Literature DB >> 11142761

The risk of fragile X premutation expansion is lower in carriers detected by general prenatal screening than in carriers from known fragile X families.

E Geva1, Y Yaron, R Shomrat, A Ben-Yehuda, S Zabari, H Peretz, T Naiman, H Yeger, A Orr-Urtreger.   

Abstract

The Fragile X syndrome is the most common cause of inherited mental retardation. For a female premutation carrier, the risk of having a child with a full mutation is positively correlated with the size of the premutation. The current study was performed to evaluate the risk of premutation expansion in the offspring of average-risk carriers detected by general prenatal screening. Over a 4-year period, 9,660 women underwent DNA screening for FMR1 mutation/premutation at the Tel Aviv Sourasky Medical Center. A premutation was defined as a CGG repeat number >50 in the 5' untranslated region (UTR) of exon 1 in the FMR1 gene. The study included only individuals with no family history of X-linked mental retardation or known FMR1 mutations. A premutation was found in 85 women (1 in 114), 68 of whom consented to have prenatal diagnoses in 74 pregnancies. The abnormal allele was transmitted to the offspring in 44 pregnancies. Of these, no change in allele size was noted in 35 pregnancies (79.6%), and expansion within premutation range was evident in 4 pregnancies (9%). In 5 pregnancies (11.4%), expansion to the full mutation was noted. This occurred only in carriers having more than 90 repeats. We conclude that the likelihood of Fragile X premutation expansion to full mutation is significantly lower in individuals ascertained by general prenatal carrier testing than in those from known Fragile X families.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11142761     DOI: 10.1089/10906570050501524

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  8 in total

1.  Carrier screening in preconception consultation in primary care.

Authors:  Sylvia A Metcalfe
Journal:  J Community Genet       Date:  2011-12-20

2.  The fragile x mental retardation syndrome 20 years after the FMR1 gene discovery: an expanding universe of knowledge.

Authors:  François Rousseau; Yves Labelle; Johanne Bussières; Carmen Lindsay
Journal:  Clin Biochem Rev       Date:  2011-08

3.  A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations.

Authors:  Flora Tassone; Ruiqin Pan; Khaled Amiri; Annette K Taylor; Paul J Hagerman
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

Review 4.  FMR1 and the fragile X syndrome: human genome epidemiology review.

Authors:  D C Crawford; J M Acuña; S L Sherman
Journal:  Genet Med       Date:  2001 Sep-Oct       Impact factor: 8.822

5.  Offering fragile X syndrome carrier screening: a prospective mixed-methods observational study comparing carrier screening of pregnant and non-pregnant women in the general population.

Authors:  M Martyn; V Anderson; A Archibald; R Carter; J Cohen; M Delatycki; S Donath; J Emery; J Halliday; M Hill; L Sheffield; H Slater; F Tassone; S Younie; S Metcalfe
Journal:  BMJ Open       Date:  2013-09-10       Impact factor: 2.692

Review 6.  Fragile X-Associated Diminished Ovarian Reserve and Primary Ovarian Insufficiency from Molecular Mechanisms to Clinical Manifestations.

Authors:  Limor Man; Jovana Lekovich; Zev Rosenwaks; Jeannine Gerhardt
Journal:  Front Mol Neurosci       Date:  2017-09-12       Impact factor: 5.639

7.  ATR protects the genome against CGG.CCG-repeat expansion in Fragile X premutation mice.

Authors:  Ali Entezam; Karen Usdin
Journal:  Nucleic Acids Res       Date:  2007-12-26       Impact factor: 16.971

8.  FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States.

Authors:  Flora Tassone; Ka Pou Iong; Tzu-Han Tong; Joyce Lo; Louise W Gane; Elizabeth Berry-Kravis; Danh Nguyen; Lisa Y Mu; Jennifer Laffin; Don B Bailey; Randi J Hagerman
Journal:  Genome Med       Date:  2012-12-21       Impact factor: 11.117

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.